Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Excess risk for contralateral breast cancer in CHEK2*1100delC germline mutation carriers.

Breast cancer research and treatment - 1 Jan 2004

Broeks Annegien, de Witte Lot, Nooijen Anke, Huseinovic Angelina, Klijn Jan G M, van Leeuwen Flora E, Russell Nicola S, van't Veer Laura J

Abstract excerpt

We detected a significant excess risk for CHEK2*1100delC mutation carriers to develop a contralateral breast tumor, OR = 6.5 (95% CI 1.5-28.8, p = 0.005). The highest percentage of mutation carriers was detected among those bilateral breast cancer patients who had received radiation treatment for their first breast tumor. These results warrant prolonged medical surveillance and may indicate a clinically important...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to Checkpoint Kinase 2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CHEK2 gene

Share to Genetic Predisposition to Disease

Share to Germ-Line Mutation

Share to Heterozygote

Share to Netherlands

Share to Protein Serine-Threonine Kinases

Source

Identifiers

PMID: 14997059
DOI: 10.1023/B:BREA.0000010697.49896.03

Genes

CHEK2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Excess risk for contralateral breast cancer in CHEK2*1100delC germline mutation carriers.PMID 14997059Read ↗

Risk for contralateral breast cancer among carriers of the CHEK2*1100delC mutation in the WECARE Study.Semantic proximity Read ↗

Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapy.Semantic proximity Read ↗

Radiation Treatment, ATM, BRCA1/2, and CHEK2*1100delC Pathogenic Variants and Risk of Contralateral Breast Cancer.Semantic proximity Read ↗

Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival.Semantic proximity Read ↗

Identification of women with an increased risk of developing radiation-induced breast cancer: a case only study.Semantic proximity Read ↗

The CHEK2*1100delC allelic variant and risk of breast cancer: screening results from the Breast Cancer Family Registry.Semantic proximity Read ↗

Breast Cancer Survival and Tumor Characteristics in Premenopausal Women Carrying the <i>CHEK2*1100delC</i> Germline MutationSemantic proximity Read ↗

Increased risk of breast cancer associated with CHEK2*1100delC.Semantic proximity Read ↗

Increased Risk for Other Cancers in Addition to Breast Cancer for CHEK2*1100delC Heterozygotes Estimated From the Copenhagen General Population Study.Semantic proximity Read ↗

Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survivalSemantic proximity Read ↗

Family history, genetic testing, and clinical risk prediction: pooled analysis of CHEK2 1100delC in 1,828 bilateral breast cancers and 7,030 controls.Semantic proximity Read ↗

Thyroid Cancer Following Breast Cancer in CHEK2 Carriers: Surveillance, Treatment or Genetic Susceptibility?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.